Scinai Immunotherapeutics (SCNI) Total Current Liabilities (2017 - 2026)

Scinai Immunotherapeutics has reported Total Current Liabilities for 10 years, with the latest figure at $2.7 million in Q1 2026.

• Quarterly Total Current Liabilities changed N/A year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, down 12.24% from the prior year.
• Total Current Liabilities climbed to $2.7 million in Q1 2026 per SCNI's latest filing, from $1.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $6.7 million in Q2 2022 and troughed at $1.4 million in Q3 2024.
• A 5-year average of $2.3 million and a median of $1.8 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities slumped 93.2% in 2022, then grew 26.79% in 2025.
• Over 5 years, Total Current Liabilities stood at $2.3 million in 2022, then slipped by 23.87% to $1.8 million in 2023, then increased by 1.46% to $1.8 million in 2024, then declined by 12.24% to $1.6 million in 2025, then surged by 69.4% to $2.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.7 million, $1.6 million, and $2.1 million for Q1 2026, Q4 2025, and Q2 2025 respectively.